Meclofenamate elicits a nephropreventing effect in a rat model of ischemic acute kidney injury by suppressing indoxyl sulfate production and restoring renal organic anion transporters

Drug Design, Development and Therapy

Volumn 8, Issue , 2014, Pages 1073-1082

  Saigo, Chika ^a   Nomura, Yui ^a   Yamamoto, Yuko ^a   Sagata, Masataka ^a   Matsunaga, Rika ^a   Jono, Hirofumi ^a,b   Nishi, Kazuhiko ^b   Saito, Hideyuki ^a,b  

^a KUMAMOTO UNIVERSITY   (Japan)

^b KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Hepatic sulfotransferase; Renal ischemia reperfusion; Renal tubular cell; Uremic toxins

Indexed keywords

APIGENIN; BOLDINE; CATECHIN; CREATININE; DICLOFENAC; ESCULETIN; GRAVEOLINE; INDICAN; MECLOFENAMIC ACID; MYRICETIN; NARINGENIN; ORGANIC ANION TRANSPORTER 1; ORGANIC ANION TRANSPORTER 3; POLYPHENOL DERIVATIVE; PROSTAGLANDIN E2; SULFOTRANSFERASE; UNCLASSIFIED DRUG; UREA; NONSTEROID ANTIINFLAMMATORY AGENT; ORGANIC ANION TRANSPORTER; POLYPHENOL;

ACUTE KIDNEY FAILURE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BASOLATERAL MEMBRANE; CELL FRACTIONATION; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOWN REGULATION; DRUG BLOOD LEVEL; DRUG LIVER LEVEL; DRUG STRUCTURE; ENZYME INHIBITION; IC 50; KIDNEY ISCHEMIA; MALE; NONHUMAN; PHYTOCHEMISTRY; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT; RENAL PROTECTION; REPERFUSION INJURY; STRUCTURE ANALYSIS; UREA NITROGEN BLOOD LEVEL; ACUTE KIDNEY INJURY; ANIMAL; BLOOD; DISEASE MODEL; DRUG EFFECTS; GENETICS; IC50; LIVER; METABOLISM; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

ACUTE KIDNEY INJURY; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD UREA NITROGEN; CREATININE; DISEASE MODELS, ANIMAL; DOWN-REGULATION; INDICAN; INHIBITORY CONCENTRATION 50; LIVER; MALE; MECLOFENAMIC ACID; ORGANIC ANION TRANSPORTERS; POLYPHENOLS; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY;

EID: 84906245212     PISSN: None     EISSN: 11778881     Source Type: Journal    
DOI: 10.2147/DDDT.S67456     Document Type: Article

References (34)

1. Cruz DN, Ricci Z, Ronco C. Clinical review: RIFLE and AKIN - time for reappraisal. Crit Care. 2009;13(3):211-219.
2. Murray PT, Devarajan P, Levey AS, et al. A framework and key research questions in AKI diagnosis and staging in different environments. Clin J Am Soc Nephrol. 2008;3(3):864-868.
3. Vanholder R, De Smet R, Glorieux G, et al. Review on uremic toxins: classification, concentration, and interindividual variability. Kidney Int. 2003;63(5):1934-1943.
4. Neirynck N, Vanholder R, Schepers E, et al. An update on uremic toxins. Int Urol Nephrol. 2013;45(1):139-150.
5. Niwa T. Indoxyl sulfate is a nephro-vascular toxin. J Ren Nutr. 2010; 20(Suppl 5):S2-S6.
6. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120. Ther Apher Dial. 2011;15(2):120-124.
7. Vincent JL. Acute kidney injury, acute lung injury and septic shock: how does mortality compare? Contrib Nephrol. 2011;174:71-77.
8. Liu KD, Matthay MA. Advances in critical care for the nephrologist: acute lung injury/ARDS. Clin J Am Soc Nephrol. 2008;3(2):578-586.
9. May CN, Calzavacca P, Ishikawa K, et al. Novel targets for sepsis-induced kidney injury: the glomerular arterioles and the sympathetic nervous system. Exp Physiol. 2012;97(11):1168-1177.
10. Herget-Rosenthal S, Glorieux G, Jankowski J, Jankowski V. Uremic toxins in acute kidney injury. Semin Dial. 2009;22(4):445-448.
11. Saito H. Toxico-pharmacological perspective of the Nrf2-Keap1 defense system against oxidative stress in kidney diseases. Biochem Pharmacol. 2013;85(7):865-872.
12. Bagshaw SM, Hoste EA, Braam B, et al. Cardiorenal syndrome type 3: pathophysiologic and epidemiologic considerations. Contrib Nephrol. 2013;182:137-157.
13. Vanholder R, Schepers E, Pletinck A, Neirynck N, Glorieux G. An update on protein-bound uremic retention solutes. J Ren Nutr. 2012;22(1):90-94.
14. Chiang CK, Tanaka T, Nangaku M. Dysregulated oxygen metabolism of the kidney by uremic toxins: review. J Ren Nutr. 2012;22(1):77-80.
15. Banoglu E, King RS. Sulfation of indoxyl by human and rat aryl (phenol) sulfotransferases to form indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2002;27(2):135-140.
16. Banoglu E, Jha GG, King RS. Hepatic microsomal metabolism of indole to indoxyl, a precursor of indoxyl sulfate. Eur J Drug Metab Pharmacokinet. 2001;26(4):235-240.
17. Enomoto A, Takeda M, Tojo A, et al. Role of organic anion transporters in the tubular transport of indoxyl sulfate and the induction of its nephrotoxicity. J Am Soc Nephrol. 2002;13(7):1711-1720.
18. Miyazaki T, Ise M, Hirata M, et al. Indoxyl sulfate stimulates renal synthesis of transforming growth factor-beta 1 and progression of renal failure. Kidney Int Suppl. 1997;63:S211-S214.
19. Iwata K, Watanabe H, Morisaki T, et al. Involvement of indoxyl sulfate in renal and central nervous system toxicities during cisplatin-induced acute renal failure. Pharm Res. 2007;24(4):662-671.
20. Morisaki T, Matsuzaki T, Yokoo K, et al. Regulation of renal organic ion transporters in cisplatin-induced acute kidney injury and uremia in rats. Pharm Res. 2008;25(11):2526-2533.
21. Kusumoto M, Kamobayashi H, Sato D, et al. Alleviation of cisplatin-induced acute kidney injury using phytochemical polyphenols is accompanied by reduced accumulation of indoxyl sulfate in rats. Clin Exp Nephrol. 2011;15(6):820-830.
22. Matsuzaki T, Watanabe H, Yoshitome K, et al. Downregulation of organic anion transporters in rat kidney under ischemia/reperfusion-induced acute renal failure. Kidney Int. 2007;71(6):539-547.
23. Schneider R, Meusel M, Renker S, et al. Low-dose indomethacin after ischemic acute kidney injury prevents downregulation of Oat1/3 and improves renal outcome. Am J Physiol Renal Physiol. 2009;297(6):F1614-F1621.
24. Wong CC, Williamson G. Inhibition of hydroxycinnamic acid sulfation by flavonoids and their conjugated metabolites. Biofactors. 2013;39(6):644-651.
25. Kimura Y, Ito H, Ohnishi R, Hatano T. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9 activity. Food Chem Toxicol. 2010;48(1):429-435.
26. Li C, Lim SC, Kim J, Choi JS. Effects of myricetin, an anticancer compound, on the bioavailability and pharmacokinetics of tamoxifen and its main metabolite, 4-hydroxytamoxifen, in rats. Eur J Drug Metab Pharmacokinet. 2011;36(3):175-182.
27. Eaton EA, Walle UK, Lewis AJ, et al. Flavonoids, potent inhibitors of the human P-form phenolsulfotransferase. Potential role in drug metabolism and chemoprevention. Drug Metab Dispos. 1996;24(2):232-237.
28. De Santi C, Pietrabissa A, Spisni R, Mosca F, Pacifici GM. Sulphation of resveratrol, a natural compound present in wine, and its inhibition by natural flavonoids. Xenobiotica. 2000;30(9):857-866.
29. King RS, Ghosh AA, Wu J. Inhibition of human phenol and estrogen sulfotransferase by certain non-steroidal anti-inflammatory agents. Curr Drug Metab. 2006;7(7):745-753.
30. Vietri M, De Santi C, Pietrabissa A, et al. Fenamates and the potent inhibition of human liver phenol sulphotransferase. Xenobiotica. 2000;30(2):111-116.
31. Sauvant C, Holzinger H, Gekle M. Prostaglandin E2 inhibits its own renal transport by downregulation of organic anion transporters rOAT1 and rOAT3. J Am Soc Nephrol. 2006;17(1):46-53.
32. Myers SI, Wang L, Liu F, Bartula LL. Suprarenal aortic clamping and reperfusion decreases medullary and cortical blood flow by decreased endogenous renal nitric oxide and PGE2 synthesis. J Vasc Surg. 2005;42(3):524-531.
33. Tokuyama H, Hayashi K, Matsuda H, et al. Role of nitric oxide and prostaglandin E2 in acute renal hypoperfusion. Nephrology (Carlton). 2003;8(2):65-71.
34. Tokuyama H, Hayashi K, Matsuda H, et al. Stenosis-dependent role of nitric oxide and prostaglandins in chronic renal ischemia. Am J Physiol Renal Physiol. 2002;282(5):F859-F865.